The therapeutic index in asthma: how should it be defined

被引:1
作者
Roche, N
Advenier, C
Huchon, G
机构
[1] Hop Hotel Dieu, Serv Pneumol & Reanimat, F-75004 Paris, France
[2] Fac Med St Peres, UPRES EA 220, Lab Pharmacol Resp, Paris, France
关键词
asthma; therapeutic index; efficacy; potency; side-effects; beta2agonists; inhaled corticosteroids; xanthines; leukotriene receptor antagonists;
D O I
10.1016/S0761-8425(04)71355-8
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction The therapeutic index (efficacy/tolerance or benefit/risk ratio) is a major determinant of treatment decisions in asthma. Methods For the numerator, the therapeutic index depends on efficacy (maximal effect) and not potency (dose-response relationship). With regard to the denominator, several pharmacological factors influence the occurrence of side-effects, the acceptability of which also has to be considered. Results In asthma, some strategies have a more favourable therapeutic index than others; e.g additional treatment (long acting beta2 agonists, leukotriene receptor antagonists, theophylline) to inhaled corticosteroids instead of doubling the dose of the latter. Conversely, it is extremely difficult to compare the therapeutic indices of different molecules of inhaled corticosteroids. Conclusions The potential risk of systemic side effects with long-term administration of high doses of inhaled corticosteroids suggests the need to seek the minimal effective dose.
引用
收藏
页码:511 / 520
页数:10
相关论文
共 53 条
[1]  
Abramson Michael J, 2003, Am J Respir Med, V2, P287
[2]   Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses [J].
Affrime, MB ;
Kosoglou, T ;
Thonoor, CM ;
Flannery, BE ;
Herron, JM .
CHEST, 2000, 118 (06) :1538-1546
[3]  
Allen David B, 2003, J Allergy Clin Immunol, V112, pS1, DOI 10.1016/S0091-6749(03)01859-1
[4]   A bolus of inhaled budesonide rapidly reverses airway subsensitivity and β2-adrenoceptor down-regulation after regular inhaled formoterol [J].
Aziz, I ;
Lipworth, BJ .
CHEST, 1999, 115 (03) :623-628
[5]   Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids [J].
Barnes, PJ .
EUROPEAN RESPIRATORY JOURNAL, 2002, 19 (01) :182-191
[6]   Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial [J].
Bjermer, L ;
Bisgaard, H ;
Bousquet, J ;
Fabbri, LM ;
Greening, AP ;
Haahtela, T ;
Holgate, ST ;
Picado, C ;
Menten, J ;
Dass, SB ;
Leff, JA ;
Polos, PG .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7420) :891-895
[7]   Comparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide [J].
Boobis, AR .
RESPIRATORY MEDICINE, 1998, 92 :2-6
[8]   A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma [J].
Bousquet, J ;
Ben-Joseph, R ;
Messonnier, M ;
Alemao, E ;
Gould, AL .
CLINICAL THERAPEUTICS, 2002, 24 (01) :1-20
[9]   CUTANEOUS VASOCONSTRICTOR RESPONSE TO GLUCOCORTICOIDS IN ASTHMA [J].
BROWN, PH ;
TEELUCKSINGH, S ;
MATUSIEWICZ, SP ;
GREENING, AP ;
CROMPTON, GK ;
EDWARDS, CRW .
LANCET, 1991, 337 (8741) :576-580
[10]   Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma [J].
Busse, W ;
Nelson, H ;
Wolfe, J ;
Kalberg, C ;
Yancey, SW ;
Rickard, KA .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 103 (06) :1075-1080